Jin Zhang
Publication Activity (10 Years)
Years Active: 2021-2024
Publications (10 Years): 13
Publications (10 Years): 13
Publications
- Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin ShaoQL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)
- Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin ShaoQL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer (2024)
- Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin ShaoQL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)
- Wenjia Zuo, Zhonghua Wang, Jun Qian, Xiaopeng Ma, Zhaofeng Niu, Jianghua Ou, Qinguo Mo, Jing Sun, Xinzheng Li, Qitang Wang, Yongzhong Yao, Guohua Yu, Hongsheng Li, Dedian Chen, Hao Zhang, Cuizhi Geng, Guangdong Qiao, Mengmeng Zhao, Baihui Zhang, Xiaoyan Kang, Jin Zhang, Zhimin ShaoQL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. British journal of cancer 131 (4) (2024)
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Shaorong Zhao, Teng Pan, Jinhai Deng, Lixia Cao, Jose M Vicencio, Jingjing Liu, Guanglin Zhou, Tony T Ng, Jin Zhang
- Yufan Qiu, Yi Yang, Ri-Yao Yang, Chunxiao Liu, Jung-Mao Hsu, Zhou Jiang, Linlin Sun, Yongkun Wei, Chia-Wei Li, Dihua Yu, Jin Zhang, Mien-Chie Hung
- Jingjing Liu, Jin Zhang